ArticlePloS one

Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma.

Michael J Harvey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.